Skip to main content

Table 2 Evidence implicating Fyn in amyloid-beta oligomer action of Alzheimer’s disease

From: Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

Observation Detail References
Increased Fyn in AD Co-localized with Tau [29]
Amyloid-beta activates Fyn Oligomer specific and PrP mediated [14]
Fyn impairs synapse N-methyl-d-aspartate receptor and dendritic spine loss [24]
Fyn interacts with Tau Localizes and phosphorylates Tau [6163]
Fyn alters AD transgenics Fyn loss protects and Fyn gain accelerates [61, 64, 65]
  1. AD, Alzheimer’s disease; PrP, prion protein.